CHRS
CHRS
NASDAQ · Biotechnology

Coherus Oncology Inc

$1.13
+0.00 (+0.00%)
As of Sep 28, 2:35 PM ET ·
Financial Highlights (FY 2026)
Revenue
52.28M
Net Income
208.30M
Gross Margin
67.2%
Profit Margin
398.4%
Rev Growth
-41.5%
D/E Ratio
0.84
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.2% 67.2% 57.2% 57.2%
Operating Margin -429.5% -386.6% -23.8% -20.0%
Profit Margin 398.4% 378.5% -24.2% -22.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 52.28M 89.42M 45.49M 44.34M
Gross Profit 35.16M 60.13M 26.00M 25.35M
Operating Income -224,561,237 -345,656,085 -10,840,195 -8,888,953
Net Income 208.30M 320.63M -11,017,037 -10,122,519
Gross Margin 67.2% 67.2% 57.2% 57.2%
Operating Margin -429.5% -386.6% -23.8% -20.0%
Profit Margin 398.4% 378.5% -24.2% -22.8%
Rev Growth -41.5% -41.5% +9.2% +11.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 41.36M 41.36M 52.40M 52.30M
Total Equity 49.41M 49.41M 72.90M 71.12M
D/E Ratio 0.84 0.84 0.72 0.74
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -219,705,299 -356,969,444 -13,211,435 -14,610,213
Free Cash Flow — — -11,236,120 -8,740,023